TTM
$10.48B
YoY change
+6.6%
5Y CAGR
+5.1%
Peak year (2021)
$12.16B
Cumulative EBITDA
$218.42B
EBITDA history chart for Abbott Laboratories (ABT) from 1985 to 2025
Latest: $11.55B
EBITDA growth chart for Abbott Laboratories (ABT) from 1985 to 2025
Latest: +6.6%
EBITDA history table for Abbott Laboratories (ABT) from 1985 to 2025
| 2025 | $11.55B | +6.6% | +$719.00M | ||
| 2024 | $10.83B | +2.2% | +$229.00M | ||
| 2023 | $10.61B | -10.8% | −$1.28B | ||
| 2022 | $11.89B | -2.2% | −$271.00M | ||
| 2021 | $12.16B | +35.1% | +$3.16B | ||
| 2020 | $9.00B | +13.8% | +$1.09B | ||
| 2019 | $7.91B | +15.0% | +$1.03B | ||
| 2018 | $6.88B | +12.2% | +$748.00M | ||
| 2017 | $6.13B | +99.7% | +$3.06B | ||
| 2016 | $3.07B | -36.5% | −$1.76B | ||
| 2015 | $4.83B | +16.3% | +$678.00M | ||
| 2014 | $4.16B | +15.3% | +$551.00M | ||
| 2013 | $3.60B | +3.1% | +$108.00M | ||
| 2012 | $3.50B | -62.2% | −$5.76B | ||
| 2011 | $9.26B | +1.3% | +$122.40M | ||
| 2010 | $9.14B | -3.7% | −$355.67M | ||
| 2009 | $9.49B | +15.4% | +$1.27B | ||
| 2008 | $8.22B | +18.9% | +$1.31B | ||
| 2007 | $6.92B | +62.7% | +$2.67B | ||
| 2006 | $4.25B | -31.7% | −$1.97B | ||
| 2005 | $6.22B | +10.8% | +$605.71M | ||
| 2004 | $5.61B | +33.6% | +$1.41B | ||
| 2003 | $4.20B | -2.4% | −$101.58M | ||
| 2002 | $4.30B | -2.0% | −$89.18M | ||
| 2001 | $4.39B | +3.9% | +$164.44M | ||
| 2000 | $4.23B | +6.3% | +$250.71M | ||
| 1999 | $3.98B | +1.9% | +$73.50M | ||
| 1998 | $3.90B | +9.6% | +$340.90M | ||
| 1997 | $3.56B | +7.9% | +$259.70M | ||
| 1996 | $3.30B | +12.0% | +$353.87M | ||
| 1995 | $2.95B | +11.1% | +$294.62M | ||
| 1994 | $2.65B | +10.2% | +$246.66M | ||
| 1993 | $2.41B | +23.2% | +$454.25M | ||
| 1992 | $1.95B | +0.9% | +$17.80M | ||
| 1991 | $1.94B | +9.9% | +$174.00M | ||
| 1990 | $1.76B | +15.3% | +$233.50M | ||
| 1989 | $1.53B | +11.3% | +$155.60M | ||
| 1988 | $1.37B | +9.9% | +$123.50M | ||
| 1987 | $1.25B | +15.9% | +$171.30M | ||
| 1986 | $1.08B | +20.7% | +$185.20M | ||
| 1985 | $892.90M | — | — |
- 2025$11.55B+6.6%
- 2024$10.83B+2.2%
- 2023$10.61B-10.8%
- 2022$11.89B-2.2%
- 2021$12.16B+35.1%
- 2020$9.00B+13.8%
- 2019$7.91B+15.0%
- 2018$6.88B+12.2%
- 2017$6.13B+99.7%
- 2016$3.07B-36.5%
- 2015$4.83B+16.3%
- 2014$4.16B+15.3%
- 2013$3.60B+3.1%
- 2012$3.50B-62.2%
- 2011$9.26B+1.3%
- 2010$9.14B-3.7%
- 2009$9.49B+15.4%
- 2008$8.22B+18.9%
- 2007$6.92B+62.7%
- 2006$4.25B-31.7%
- 2005$6.22B+10.8%
- 2004$5.61B+33.6%
- 2003$4.20B-2.4%
- 2002$4.30B-2.0%
- 2001$4.39B+3.9%
- 2000$4.23B+6.3%
- 1999$3.98B+1.9%
- 1998$3.90B+9.6%
- 1997$3.56B+7.9%
- 1996$3.30B+12.0%
- 1995$2.95B+11.1%
- 1994$2.65B+10.2%
- 1993$2.41B+23.2%
- 1992$1.95B+0.9%
- 1991$1.94B+9.9%
- 1990$1.76B+15.3%
- 1989$1.53B+11.3%
- 1988$1.37B+9.9%
- 1987$1.25B+15.9%
- 1986$1.08B+20.7%
- 1985$892.90M—
EBITDA values are taken from Abbott Laboratories's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Abbott Laboratories (ABT)
According to Abbott Laboratories's latest reported financial statements, the company's current EBITDA (TTM) is $10.48B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Abbott Laboratories (ABT) EBITDA totalled $11.55B – grew 6.6% year-over-year.
Over 2020–2025 (5 years), Abbott Laboratories EBITDA expanded at a +5.1% compound annual rate, sustaining 2 straight years of year-over-year growth.
Abbott Laboratories EBITDA peaked at $12.16B in 2021; the latest annual figure is $11.55B in 2025 (5.0% below peak).
2021 marks the peak EBITDA at $12.16B, with the historical low of $892.90M recorded in 1985.
Abbott Laboratories EBITDA by Year
Abbott Laboratories EBITDA 2025: $11.55B
In 2025, Abbott Laboratories reported EBITDA of $11.55B, grew 6.6% from 2024.
Abbott Laboratories EBITDA 2024: $10.83B
Abbott Laboratories EBITDA in 2024 was $10.83B, edged up 2.2% from 2023.
Abbott Laboratories EBITDA 2023: $10.61B
2023's EBITDA for Abbott Laboratories came in at $10.61B, declined 10.8% below 2022.
Abbott Laboratories EBITDA 2022: $11.89B
Abbott Laboratories posted EBITDA of $11.89B in 2022, edged down 2.2% below 2021.
Abbott Laboratories EBITDA 2021: $12.16B
Abbott Laboratories EBITDA in 2021 was $12.16B.
See more financial history for Abbott Laboratories (ABT).
Sector peers by EBITDA
Healthcare peers of Abbott Laboratories (ABT), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation